Skip to main
ALZN
ALZN logo

Alzamend Neuro (ALZN) Stock Forecast & Price Target

Alzamend Neuro (ALZN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alzamend Neuro Inc. has demonstrated significant progress in its clinical pipeline for addressing neurodegenerative diseases and psychiatric disorders, particularly with the positive top-line results reported in June 2023. The company's innovative drug candidates, AL001 and AL002, leverage novel therapeutic approaches that could potentially transform treatment options in the Alzheimer's market, indicating strong developmental promise. Additionally, the current valuation of the company remains attractive, suggesting potential upside based on a net present value analysis that reflects the market's recognition of the company's growth potential and upcoming milestones.

Bears say

Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded estimates of $(0.69). The company operates in the high-risk biopharmaceutical sector, where the development of novel treatments for neurodegenerative diseases faces numerous challenges, including the need for securing regulatory approvals and demonstrating product efficacy in clinical trials. Additionally, potential liquidity and balance sheet risks, coupled with a competitive and changing healthcare landscape, contribute to a negative outlook for the company's financial stability and stock performance.

Alzamend Neuro (ALZN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alzamend Neuro (ALZN) Forecast

Analysts have given Alzamend Neuro (ALZN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Alzamend Neuro (ALZN) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alzamend Neuro (ALZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.